Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nur Nicholson Insider Profile
4 Followers
Nur Nicholson, CTO at Apellis Pharmaceuticals, holds 83.66K shares in Apellis Pharmaceuticals (Ticker: APLS). Most recently, Nur Nicholson Sold $825 shares of Apellis Pharmaceuticals on Jan 30, 2025 for an estimated value of 24.35K.
Profitable Transactions
8 out of 9 Profitable Transactions
Average Return
+26.40%
Average return per transaction
Time Frame
Compare to
Insider Roles
CTO
Roles that Nur Nicholson holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Jan 17, 2024 - Jan 17, 2025
Return:+54.50%
The most profitable trade made by Nur Nicholson
Nur Nicholson's Trading History
List of latest transactions for each holding click on a transaction to see Nur Nicholson's performance on stock
You May Also Like
Nur Nicholson insider profile FAQ
What is the percentage of profitable transactions made by Nur Nicholson?
The percentage of profitable transactions made by Nur Nicholson is 89%.
What is the average return per transaction made by Nur Nicholson?
The average return per transaction made by Nur Nicholson is 26.40%.
What stocks does Nur Nicholson hold?
Nur Nicholson holds: APLS stocks.
What was Nur Nicholson’s latest transaction?
Nur Nicholson latest transaction was an Informative Sell of $24.35K.
What was Nur Nicholson's most profitable transaction?
Nur Nicholson’s most profitable transaction was an Informative Sell of APLS stock on January 17, 2024. The return on the trade was 54.50%.
What is Nur Nicholson's role in Apellis Pharmaceuticals?
Nur Nicholson's role in Apellis Pharmaceuticals is CTO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.